Don M. Hardison, President and Chief Executive Officer of EXACT Sciences Corporation, preside over the Market Close

Friday, March 16, 2007
at NASDAQ's MarketSite
in New York City.

EXACT Sciences Corporation
[EXAS]

EXACT Sciences Corporation is applying advances in genomics to facilitate the early detection of common cancers. The Company's stool-based, DNA technology offers the most accurate, non-invasive diagnostic available for the detection of colorectal cancer (CRC). CRC is the 2nd leading cause of cancer deaths and according to the American Cancer Society's journal, screening has been shown to have the biggest impact on improving mortality, over treatment and behavior modification. Despite this, more than half of the 87 million people over the age of 50 who should be adequately screened are not, and this rate increases by approximately four million each year.

EXACT Sciences has a commercial partnership with Laboratory Corporation of America (LabCorp.), which offers a simple, non-invasive CRC screening test based on EXACT's proprietary technologies. EXACT Sciences also aims to exploit new opportunities within CRC, such as staging and monitoring, and pursue new opportunities in other cancers.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 03/16/2007 Download Hi-Res Quality Photo of this NASDAQ Market Close - Pictured: Don M. Hardison, President and Chief Executive Officer of EXACT Sciences Corporation, signs the podium at the closing bell. These photos are Copyright 2007, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2007, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.